• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Integer Holdings Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/28/25 7:08:15 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email
    gb-20250521
    0001114483false12/3100011144832025-05-212025-05-21

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549 
    _____________________________________
    FORM 8-K
    _____________________________________
     CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of report (Date of earliest event reported):May 21, 2025
    itgrlogo20190925a11.jpg
    INTEGER HOLDINGS CORPORATION
    (Exact name of registrant as specified in its charter)
    _____________________________________
    Delaware1-1613716-1531026
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    5830 Granite Parkway,Suite 1150Plano,Texas 75024
    (Address of principal executive offices) (Zip Code)
    (214) 618-5243
    Registrant’s telephone number, including area code
    _____________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par value per shareITGRNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
                                                Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
    As further described below in Item 5.07 of this Current Report on Form 8-K, on May 21, 2025, at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Integer Holdings Corporation (the “Company”), the Company's stockholders approved an amendment (the "Amendment”) to the Company's Restated Certificate of Incorporation, as amended (the “Charter”), to provide for the elimination of monetary liability of certain officers of the Company in certain circumstances as permitted by Delaware law. On May 23, 2025, the Company filed a Certificate of Amendment to the Charter that sets forth the Amendment (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware.
    A description of the Amendment is set forth in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 7, 2025, in the section entitled “Proposal 4 – Approval of an Amendment to the Company's Restated Certificate of Incorporation (Officer Exculpation).” The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
    Additionally, on May 21, 2025, the Company's Board of Directors (the “Board”) approved an amendment to the Company’s Bylaws (the “Amended and Restated Bylaws”), which became effective immediately.
    The only change effected by the amendment to the Amended and Restated Bylaws was to delete in full former Article 9, which permitted ratification of prior actions by the Board or by the Company's stockholders. The foregoing description of the amendment to the Amended and Restated Bylaws is qualified in its entirety by reference to, and should be read in conjunction with, the text of the Amended and Restated Bylaws. The Amended and Restated Bylaws, along with a copy marked to show changes from the prior version, are included as Exhibits 3.2 and 3.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
    Item 5.07. Submission of Matters to a Vote of Security Holders.
    At the Annual Meeting held on May 21, 2025, the proposals listed below were submitted to a vote of the stockholders. The proposals are described in the Company's definitive proxy statement for the Annual Meeting previously filed with the Securities and Exchange Commission. Each of the proposals was approved by the stockholders pursuant to the voting results set forth below.
    Proposal 1: To elect 10 directors for a one-year term until their successors have been elected and qualified:
    Name:Shares FOR:Shares WITHHELD:Broker
    NON VOTE:
    Sheila Antrum32,545,46355,576963,255
    Pamela G. Bailey31,471,8701,129,169963,255
    Cheryl C. Capps32,543,90657,133963,255
    Joseph W. Dziedzic32,540,77460,265963,255
    James F. Hinrichs32,544,61256,427963,255
    Jean Hobby32,468,356132,683963,255
    Tyrone Jeffers32,469,313131,726963,255
    M. Craig Maxwell32,532,94368,096963,255
    Filippo Passerini32,468,667132,372963,255
    Donald J. Spence32,448,874152,165963,255
    Proposal 2: To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of Integer Holdings Corporation for fiscal year 2025:
    FOR:
    32,746,004 
    AGAINST:
    815,673 
    ABSTAINED:
    2,617 



    Proposal 3: To approve, on an advisory basis, the compensation of the Company’s named executive officers:
    FOR:
    31,879,361 
    AGAINST:
    716,649 
    ABSTAINED:
    5,029 
    Broker NON-VOTE:
    963,255 
    Proposal 4: To approve an amendment to the Company’s Restated Certificate of Incorporation to include an officer exculpation provision:
    FOR:
    27,522,559 
    AGAINST:
    5,070,544 
    ABSTAINED:
    7,936 
    Broker NON-VOTE:
    963,255 
    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit
    Number
    Description of Exhibit
    3.1
    Certificate of Amendment to the Restated Certificate of Incorporation of Integer Holdings Corporation
    3.2
    By-laws of Integer Holdings Corporation (Amended and Restated as of May 21, 2025)
    3.3
    Marked By-laws of Integer Holdings Corporation (Amended and Restated as of May 21, 2025)
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    Date:May 28, 2025INTEGER HOLDINGS CORPORATION
    By:
    /s/ Lindsay K. Blackwood
    Lindsay K. Blackwood
    Senior Vice President, General Counsel and Corporate Secretary

    Get the next $ITGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    2/20/2026$95.00Hold → Buy
    The Benchmark Company
    10/24/2025Buy → Hold
    Argus
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    10/24/2025$77.00Buy → Neutral
    Citigroup
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    10/24/2025Buy → Hold
    The Benchmark Company
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    More analyst ratings

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integer Announces Board Leadership Transition

    PLANO, Texas, April 06, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced Pamela G. Bailey, who currently serves as Integer's independent Chair of the Board, will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026. Following the Annual Meeting, the Board intends to appoint current director Donald J. Spence to serve as independent Chair of the Board. "It has been a privilege to serve on the Integer Board and to play my part in the Company's growth and strategic success," said Ms. Bailey. "I am confident that und

    4/6/26 5:00:51 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

    ~ Enters into Cooperation Agreement with Irenic Capital Management ~  PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that James Flanagan has been appointed to the Board of Directors (the "Board") as an independent director. Additionally, in connection with a cooperation agreement with Irenic Capital Management, LP (together with its affiliates, "Irenic"), Aaron Kapito has also been appointed to the Board. "The Board looks forward to welcoming James and Aaron as new independent directors and benefiting from their complementary perspectives

    3/12/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer to Participate at Upcoming Investor Conferences

    PLANO, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that members of its executive leadership team will participate in the following investor conferences in March: Raymond James 47th Annual Institutional Investors Conference, 11:35 a.m. ET, March 3Oppenheimer 36th Annual Healthcare MedTech & Services Conference, 12:40 p.m. ET, March 17KeyBanc Capital Markets Healthcare Forum, 11:15 a.m. ET, March 18 A live webcast and replay for each event will be accessible under "News & Events" on the Investor Relations section of Integer's website at investor.integer.net.

    2/24/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Ops and Manufactur Harris John A bought $115,500 worth of shares (1,650 units at $70.00), increasing direct ownership by 37% to 6,066 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/13/25 4:18:50 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Harris John A

    4 - Integer Holdings Corp (0001114483) (Issuer)

    4/2/26 4:28:54 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Kapito Aaron

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:52 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Carr Terence

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:47 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integer Holdings upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Integer Holdings from Hold to Buy and set a new price target of $95.00

    2/20/26 8:20:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Argus

    Argus downgraded Integer Holdings from Buy to Hold

    10/24/25 2:15:30 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Integer Holdings from Overweight to Equal Weight and set a new price target of $80.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    SEC Filings

    View All

    SEC Form DEFA14A filed by Integer Holdings Corporation

    DEFA14A - Integer Holdings Corp (0001114483) (Filer)

    4/6/26 4:57:04 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEF 14A filed by Integer Holdings Corporation

    DEF 14A - Integer Holdings Corp (0001114483) (Filer)

    4/6/26 4:56:04 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Integer Holdings Corporation

    SCHEDULE 13G/A - Integer Holdings Corp (0001114483) (Subject)

    3/27/26 9:55:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    View All

    Integer Announces Board Leadership Transition

    PLANO, Texas, April 06, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced Pamela G. Bailey, who currently serves as Integer's independent Chair of the Board, will not stand for re-election at the Company's 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026. Following the Annual Meeting, the Board intends to appoint current director Donald J. Spence to serve as independent Chair of the Board. "It has been a privilege to serve on the Integer Board and to play my part in the Company's growth and strategic success," said Ms. Bailey. "I am confident that und

    4/6/26 5:00:51 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

    ~ Enters into Cooperation Agreement with Irenic Capital Management ~  PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that James Flanagan has been appointed to the Board of Directors (the "Board") as an independent director. Additionally, in connection with a cooperation agreement with Irenic Capital Management, LP (together with its affiliates, "Irenic"), Aaron Kapito has also been appointed to the Board. "The Board looks forward to welcoming James and Aaron as new independent directors and benefiting from their complementary perspectives

    3/12/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Financials

    Live finance-specific insights

    View All

    Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2025

    ~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading contract development and manufacturing organization, today announced results for the three and twelve months ended December 31, 2025. Unless otherwise stated, all results and comparisons are from continuing operations. Fourth Quarter 2025 Financial Results (compared to fourth quarter 2024, except as noted) Sales increased 5% to $472 mill

    2/19/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Fourth Quarter and Full Year 2025 Results

    PLANO, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the fourth quarter and year ended Dec. 31, 2025, on Thursday, Feb. 19, 2026, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the fourth quarter and full year on Feb. 19 prior to the conference call. Conference call details: Date: Thursday, Feb. 19, 2026Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 30

    1/22/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/9/24 9:59:01 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    1/30/24 1:15:44 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/10/23 2:42:23 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care